Abiraterone acetate plus prednisolone with or without enzalutamide for patients with metastatic prostate cancer starting androgen deprivation therapy: final results from two randomised phase 3 trials of the STAMPEDE platform protocolGerhardt Attard, Robin Millman, Robert J. Jones et al.|The Lancet Oncology|2023Cited by 110
Management of Small Testicular Masses: A Delphi Consensus StudyKarl H. Pang, Asıf Muneer, Giuseppe Fallara et al.|European Urology Oncology|2024Cited by 10
1768MO Incidence of fracture related hospitalisations in men with de novo high risk localised and metastatic hormone sensitive prostate cancer: Analysis of routinely collected healthcare data from the STAMPEDE docetaxel and zoledronic acid comparisonsCraig Jones, Ashwin Sachdeva, Peter Dutey‐Magni et al.|Annals of Oncology|2023Cited by 5
Plasma <i>AR</i> Alterations and Timing of Intensified Hormone Treatment for Prostate CancerGianmarco Leone, Francesco Orlando, Peter Dutey‐Magni et al.|JAMA Oncology|2025Cited by 5